CAS: 329-01-1; 1-Isocyanato-3-(Trifluoromethyl)Benzene

上下游产品

CAS号32315-10-9 三光气 | CAS号98-16-8 间三氟甲苯胺 | CAS号75-44-5 光气 | CAS号69563-05-9 1,1,1-trimethyl... | CAS号503-38-8 氯甲酸三氯甲酯 | CAS号2164-17-2 伏草隆 | CAS号29209-09-4 2-Methyl-3-oxo-... | CAS号126938-43-0 1-phenylmethoxy... | CAS号330796-24-2 N-[4-氯-3-(三氟甲基)... | CAS号2164-17-2 伏草隆 | CAS号86927-99-3 (3-diethylamino... | CAS号88452-29-3 1-benzyl-1-buty... | CAS号88808-39-3 3-[3-(trifluoro... | CAS号78614-24-1 methyl 3-[[3-(t... | CAS号79513-91-0 1-(2,6-dimethyl... | CAS号89676-71-1 4-[3-(trifluoro...

3-三氟甲基苯甲酸置于diphenyl Phosphoryl Azide,三乙胺体系中,用 四氢呋喃,苯 用作溶剂,化学反应 3.0H,反应生成3-(三氟甲基)异氰酸苯酯
参考文献:穿心莲内酯c-14芳基氨基甲酸酯衍生物的设计,合成及抗癌评价
标题:穿心莲内酯c-14芳基氨基甲酸酯衍生物的设计,合成及抗癌评价
摘要:在这项研究中,我们探索了一种简洁,温和的合成路线来生产穿心莲内酯的新型 C-14 芳基氨基甲酸酯衍生物,穿心莲内酯是一种已知的抗炎和抗癌天然产物.在评估其对胰腺导管腺癌(Pdac) 细胞的抗癌功效后,一些衍生物对 Panc-1 细胞表现出比穿心莲内酯更强的细胞毒性.此外,我们证明了一种衍生物,化合物3M,可有效降低 Pdac 系 Panc-1 和 Mia Paca-2 中致癌 P53 突变蛋白(p53 R273H和 P53 R248W )的表达,增殖和迁移.因此,该新型衍生物有望作为抗胰腺癌的抗癌剂.总之,我们的研究拓宽了穿心莲内酯的衍生物库,并开发了一种具有非常好抗 Pdac 抗癌活性的穿心莲内酯芳基氨基甲酸酯衍生物.
Doi:10.1016/j.Bmc.2023.117582

专利信息

专利号:US-7138526-B1
优先权日:1999-06-15
标 题 :Solid phase synthesis of n,n-disubstituted diazacycloalkylcarboxy derivatives
发明人：HERPIN TIMOTHY F; MORTON GEORGE C; SALVINO JOSEPH M
权利人:AVENTIS PHARMA INC
摘要:A method for the solid phase synthesis of N,N-disubstituted diazacycloalkylcarboxy derivatives of general formula (I) and (II) is claimed. Examples include piperazine-2-carboxamide. The method is applicable to the synthesis or large combinatorial libraries

专利号:US-7897762-B2
优先权日:2006-09-14
标 题:Kinase inhibitors useful for the treatment of proliferative diseases
发明人：FLYNN DANIEL L; PETILLO PETER A; KAUFMAN MICHAEL D; PATT WILLIAM C
权利人:DECIPHERA PHARMACEUTICALS LLC
摘要:The present invention relates to novel kinase inhibitors and modulator compounds useful for the treatment of various diseases. More particularly, the invention is concerned with such compounds, kinase/compound adducts, methods of treating diseases, and methods of synthesis of the compounds. Preferably, the compounds are useful for the modulation of kinase activity of Raf kinases and disease polymorphs thereof. Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant melanoma, colorectal cancer, ovarian cancer, papillary thyroid carcinoma, non small cell lung cancer, and mesothelioma. Compounds of the present invention also find utility in the treatment of rheumatoid arthritis and retinopathies including diabetic retinal neuropathy and macular degeneration.

专利号:US-8188113-B2
优先权日:2006-09-14
标 题 :Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
发明人：FLYNN DANIEL L; PETILLO PETER A; KAUFMAN MICHAEL D; PATT WILLIAM C
权利人:FLYNN DANIEL L; PETILLO PETER A; KAUFMAN MICHAEL D; PATT WILLIAM C; DECIPHERA PHARMACEUTICALS INC
摘要:The present invention relates to novel dihydropyridopyrimidinyl, dihydronaphthyridinyl, and related compounds which are kinase inhibitors and modulator useful for the treatment of various diseases. More particularly, the invention is concerned with such compounds, kinase/compound adducts, methods of treating diseases, and methods of synthesis of the compounds. Preferably, the compounds are useful for the modulation of kinase activity of Raf kinases and disease polymorphs thereof. Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant melanoma, colorectal cancer, ovarian cancer, papillary thyroid carcinoma, non small cell lung cancer, and mesothelioma. Compounds of the present invention also find utility in the treatment of rheumatoid arthritis and retinopathies including diabetic retinal neuropathy and macular degeneration.

专利号:WO-9700244-A1
优先权日:1995-06-19
标题 :Process for parallel synthesis of a non-peptide library
发明人：FRITZ JAMES E; KALDOR STEPHEN W
权利人:LILLY CO ELI; FRITZ JAMES E; KALDOR STEPHEN W
摘要:A process for the sequential preparation of a library of compounds having pharmaceutical usage. The process involves the sequential mixing of solution phase reagents, followed by scavenging of excess unreacted reagents with solid phase scavenging agents. The process is highly iterative and applicable for producing various ureas, thiureas, amides, carbonates and tertiary amines.

专利号:US-10385167-B2
优先权日:2015-02-13
标题:Process for the synthesis of polyoxazolidinone compounds with high stability
发明人：MÃœLLER THOMAS ERNST; Gürtler Christoph; BASU SUSMIT; RANGHEARD CLAUDINE; RIVILLO DAVID; LEITNER WALTER; Köhler Burkhard
权利人:COVESTRO DEUTSCHLAND AG
摘要:The present invention relates to polyoxazolidinone compounds, a method for the production of polyoxazolidinone compounds, comprising the step of reacting a biscarbamate compound with a bisepoxide compound in the presence of a mono-carbamate, a mono-isocyanate and/or a mono-epoxide compound as chain regulator and a suitable base having a pK b value of ≤9 as catalyst. The invention further relates to the use of polyoxazolidinone compounds with high thermal stability.

专利号:US-11326018-B2
优先权日:2016-08-19
标 题:Process for the synthesis of polyoxazolidinone compounds
发明人：WEBER ANNA; RANGHEARD CLAUDINE; KESSLER MICHAEL; LEITNER WALTER; Gürtler Christoph; KOOPMANS CARSTEN; MÃœLLER THOMAS ERNST
权利人:COVESTRO DEUTSCHLAND AG
摘要:A method for the production of polyoxazolidinone compounds, comprising the step of reacting an isocyanate compound (A) with an epoxide compound (B) in the presence of a catalyst (C), wherein the isocyanate compound (A) comprises a isocyanate compound (A 1 ) wherein the a isocyanate compound (A1) comprising at least two isocyanate groups (I 1 ≥2), preferred two isocyanate groups (I 1 =2), wherein the epoxide compound (B) comprises a epoxide compound (B 1 ) and an epoxide compound (B 2 ), wherein the epoxide compound (B 2 ) is different from the epoxide compound (B 1 ) wherein the epoxide compound (B 1 ) comprising at least two terminal epoxide groups (F1≥2), preferred two terminal epoxide groups (F 1 =2), linked together by a linking group (L1) and the epoxide compound (B 2 ) comprising at least two terminal epoxide groups (F 2 ≥2)), preferred two terminal epoxide groups (F 2 =2), linked together by a linking group (L 2 ), wherein the linking group (L 2 ) comprises acyclic and covalent bonds to each other free of conjugated multiple bonds within the main chain, wherein the epoxide compound (B 2 ) is present in the epoxide compounds B 1 and B 2 , in an amount of ≥0.01 mol-% to <10 mol-%, preferred 1-9 mol-% more preferred 3-8 mol-% based on the molar ratio the terminal epoxide groups in the epoxide compound (B 1 ) and of the sum of the terminal epoxide groups in the epoxide compound (B 1 ) and terminal epoxide groups in the epoxide compound (B 2 ).